Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9792
Title: Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.
Authors: Jefford, Michael;Kiffer, John D;Somers, Gino;Daniel, Freddy J;Davis, Ian D
Affiliation: Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Victoria, Australia. michael.jefford@petermac.org
Issue Date: 1-Aug-2004
Citation: Anz Journal of Surgery; 74(8): 704-5
Abstract: Basal cell carcinoma (BCC) is the most common cancer in the community, although it rarely metastasizes. The literature reports less than 100 patients who have received chemotherapy for metastatic BCC. A further case of this rare disease is reported here. The pattern of disease in the reported patient was similar to that described in the literature, but the patient experienced a long period with untreated metastatic disease compared with that in the literature.The patient was treated with cisplatin in combination with paclitaxel. Literature review suggests this to be the first report of this combination.Rapid symptomatic response was achieved though late neurotoxicity occurred.This regimen is an active combination for the rare patient with metastatic BCC. The combination of carboplatin and paclitaxel causes less neurotoxicity and may therefore be a superior regimen.
Internal ID Number: 15315581
URI: http://ahro.austin.org.au/austinjspui/handle/1/9792
DOI: 10.1111/j.1445-1433.2004.03130.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/15315581
Type: Journal Article
Subjects: Antineoplastic Agents.therapeutic use
Carcinoma, Basal Cell.drug therapy.secondary
Cisplatin.therapeutic use
Humans
Lung Neoplasms.drug therapy.secondary
Male
Middle Aged
Paclitaxel.therapeutic use
Remission Induction
Skin Neoplasms.pathology
Time Factors
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.